Compositions and methods for targeted cytokine delivery
US-2024376169-A1 · Nov 14, 2024 · US
US8932601B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8932601-B2 |
| Application number | US-201113306631-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 29, 2011 |
| Priority date | Jan 21, 2004 |
| Publication date | Jan 13, 2015 |
| Grant date | Jan 13, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the spacer sequence. The second functional unit may be a polypeptide providing a functional unit of a second complement regulatory protein, a polypeptide derived from an immunoglobulin, or a polypeptide that enhances binding of the protein to an animal cell. The hybrid protein may also contain a second spacer sequence and a third functional unit of a complement regulatory protein, a polypeptide derived from an immunoglobulin, and a polypeptide that enhances binding of the protein to an animal cell. The optional third functional unit may be the same or different from the first or second functional units.
Opening claim text (preview).
We claim: 1. A hybrid protein consisting of: a functional unit of a complement regulatory protein, the functional unit consisting of Complement Control Protein repeats (CCPs) 2, 3 and 4 of human DAF or CCPs 1, 2, 3, and 4 of human DAF, the functional unit having decay accelerating activity against classical pathway and alternative pathway convertase, a targeting moiety that enhances binding of the hybrid protein to an animal tissue, wherein the targeting moiety is a lipid tail t…
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.